A New Standard of Care for HER2-Positive Metastatic Breast Cancer?

A New Standard of Care for HER2-Positive Metastatic Breast Cancer?

/in , , , , /by

This podcast was originally published by Dr. Rashmi Murthy on December 11, 2019 on breastcancer.org here.

Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.

Listen to the episode to hear Dr. Murthy explain:

  • A summary of the study results
  • Why this study included people with brain metastases
  • The side effects of tucatinib
  • Why she thinks the results are practice changing
You might also like
Examining the Link Between Gestational Diabetes and Breast CancerExamining the Link Between Gestational Diabetes and Breast Cancer
Which Metastatic Breast Cancer Treatment Is Right for You What You Need to KnowWhich Metastatic Breast Cancer Treatment Is Right for You? What You Need to Know
What Are Essential Genetic Tests for Metastatic Breast Cancer Patients?What Are Essential Genetic Tests for Metastatic Breast Cancer Patients?
What is Node-Positive and Node-Negative Breast Cancer?What Is Node-Positive and Node-Negative Breast Cancer?
What Factors Help Guide Metastatic Breast Cancer Treatment Decisions?
Genetic Testing VS Biomarker Testing: What’s the DifferenceGenetic Testing VS Biomarker Testing: What’s the Difference?